New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute ...

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

ATLANTA—Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/ritonavir), provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models ...

A recent study published in JAMA Network Open examined the efficacy of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized patients with coronavirus disease 2019 (COVID-19) and type 2 diabetes ...

A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...

With every new infection, the pandemic coronavirus gets new chances to mutate and adapt, creating opportunities for the virus to evolve new variants that are better at dodging our immune systems and ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant ...

"We demonstrate in two animal model species, one rodent and one non-rodent, that infectious particle titers, but not viral RNA copy numbers, should be assessed to determine efficacy of a viral mutagen ...